Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases

• Main Authors: Hongmei Tang (Author), Qin Lu (Author), Shiyin Feng (Author), Zhiwei Xiao (Author), Wanyin Wu (Author), Gaofeng Chen (Author), Li Deng (Author), Tianqi Yu (Author), Junyan Wu (Author), Hua Lin (Author), Bo Ji (Author), Jietao Lin (Author), Chengguang Zhang (Author), Liming Li (Author), Tao Liu (Author), Yong Ouyang (Author), Kaijun Lei (Author), Jun Chen (Author), Weiwen Peng (Author), Zhenwen Qiu (Author), Qingqun Cai (Author), Qi Liang (Author), Cuiling Liu (Author), Yuzhen Li (Author), Lixia Zhu (Author), Zexin Zhang (Author), Xueting Liu (Author), Lizhu Lin (Author), Zhihua Zheng (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractContext The Xihuang pill (XHP) is a traditional Chinese medicine formulation that has been historically used in the prevention and treatment of proliferative breast diseases. However, there is a lack of guidelines that offer recommendations for its clinical use.Objective The task force from...